SEGMENT INFORMATION

As a result of the Lake Region Medical acquisition and Spin-off, during 2016 the Company reorganized its operations including its internal management and financial reporting structure. As a result of this reorganization, the Company reevaluated and revised its reportable business segments during the fourth quarter of 2016 and began to disclose two reportable segments: (1) Medical and (2) Non-Medical. Prior period amounts have been reclassified to conform to the new segment reporting presentation. The two reportable segments, along with their related product lines, are described below:

Medical - includes the (i) Cardio & Vascular product line, which includes introducers, steerable sheaths, guidewires, catheters, and stimulation therapy components, subassemblies and finished devices that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery; (ii) Cardiac & Neuromodulation product line, which includes batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures used in implantable medical devices; and (iii) Advanced Surgical, Orthopedics & Portable Medical product line, which includes components, sub-assemblies, finished devices, implants, instruments and delivery systems for a range of surgical technologies to the advanced surgical market, including laparoscopy, orthopedics and general surgery, biopsy and drug delivery, joint preservation and reconstruction, arthroscopy, and engineered tubing solutions. Products also include life-saving and life-enhancing applications comprising of automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools.

Non-Medical - includes primary (lithium) cells, and primary and secondary battery packs for applications in the energy, military and environmental markets.

During the first quarter of 2017, the Company revised the method used to present sales by product line in order to align the legacy Greatbatch and Lake Region Medical methodologies. The Company believes the revised presentation will provide improved reporting and better transparency into the operational results of its business and markets. Prior period amounts have been reclassified to conform to the new product line sales reporting presentation.

(15.) SEGMENT INFORMATION (Continued)

The tables below present information about our reportable segments (in thousands):



	Three Months Ended				Nine Months Ended
	September 29, 2017		September 30, 2016		September 29, 2017		September 30, 2016
Segment sales by product line:
Medical
Cardio & Vascular	$	138,982	$	129,347	$	396,321	$	365,271
Cardiac & Neuromodulation	101,616		108,147		311,614		323,599
Advanced Surgical, Orthopedics & Portable Medical	107,581		100,203		321,287		307,956
Total Medical	348,179		337,697		1,029,222		996,826
Non-Medical	15,129		8,870		42,218		30,361
Total sales	$	363,308	$	346,567	$	1,071,440	$	1,027,187

There were no sales between segments during the nine months ended September 29, 2017 and September 30, 2016.



	Three Months Ended						Nine Months Ended
	September 29, 2017			September 30, 2016			September 29, 2017			September 30, 2016
Segment income from operations:
Medical	$	50,168		$	54,979		$	155,761		$	138,151
Non-Medical	3,375			(1,425		)	9,877			626
Total segment income from operations	53,543			53,554			165,638			138,777
Unallocated operating expenses	(14,912		)	(16,692		)	(60,723		)	(61,512		)
Operating income	38,631			36,862			104,915			77,265
Unallocated expenses, net	(26,641		)	(28,145		)	(93,004		)	(80,623		)
Income (loss) before income taxes	$	11,990		$	8,717		$	11,911		$	(3,358	)